Hans Hultberg

AstraZeneca (United Kingdom)

Papers

1

Total Citations

3

H-Index

1

About

Hans Hultberg is a distinguished researcher whose work has centered on advancing proteomics and biomarker discovery, particularly through collaborative frameworks that bridge academic and pharmaceutical sectors. His most cited paper, "Implementation of a protein profiling platform developed as an academic‐pharmaceutical industry collaborative effort" (2008, 3 citations), exemplifies his commitment to translating fundamental proteome research into practical diagnostic and prognostic tools for severe diseases. Hultberg’s major contribution lies in developing robust protein profiling platforms that enable the identification of novel biomarkers, potentially revolutionizing how diseases are detected and monitored. By fostering cross-sector partnerships, he has helped streamline the path from laboratory discovery to clinical application, addressing critical bottlenecks in biomarker validation. While his citation count may be modest, the foundational nature of his work underscores its importance in a field where reproducibility and collaboration are paramount. Hultberg’s efforts have laid essential groundwork for future innovations in precision medicine, making him a key figure in the ongoing quest to harness proteomic data for improved patient outcomes.

Research Focus

Key Achievements

1
H-Index
1
Papers
3
Total Citations
3
Avg Citations/Paper
🏆 Most Cited Paper
Implementation of a protein profiling platform developed as an academic‐pharmaceutical industry collaborative effort
3 citations · 2008
📈 Most Prolific Year: 2008 (1 Papers)
🤝 Key Collaborators: 13
🏛 Institutions: AstraZeneca (United Kingdom)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago